Skip to content

Welcome to Pharmecons Easy Access

Your Market Access & Evidence Generation Partner for Pharmaceuticals & Medical Technologies

Evidence Generation

Evidence Generation

Read More

Real World Evidence & Data Analytics

Real World Evidence & Data Analytics

Read More

Market Access

Market Access

Read More

Medical Devices & Digital Health

Medical Devices & Digital Health

Read More
BOUND TO
OUR MISSION

Through the use of our multi-disciplinary expertise from pharmaceutical and medical devices, regulatory, clinical and market access experience, we seek to provide individualized solutions to Pharma & Medical Device Industry to best support products’ added value.

HONOURING
OUR ETHOS

We pride ourselves on going the extra mile to fully satisfy our clients’ needs through rigorous research, delivered at the highest possible quality and within client-defined timelines. We honour our clients’ needs with professionalism, confidentiality and positive work ethos

SHARING
OUR VISION
Our vision is to provide expert guidance with tailor-made solutions, through every phase of product development, to leverage products’ value proposition, enabling Easy Access to our customers’ products.

OUR RECENT

NEWS & ACTIVITIES

Athens Digital Health Week 2025

The digital transformation of healthcare providers is critical for improving patient outcomes, operational efficiency, and system-wide sustainability. This session aims to explore the unique challenges and needs of healthcare providers in adopting digital solutions while highlighting their transformation journey.

Stronger Together – Pharmecons Easy Access Ltd & Exzellia Pharma Ltd.

We are excited to announce that Pharmecons Easy Access Ltd. has entered into a collaboration with Exzellia Pharma Ltd. and Dr. Stalo Charalambous. Through this partnership, Pharmecons will enhance its footprint and activities in Cyprus and Malta, leveraging Dr. Charalambous' extensive knowledge and expertise in the healthcare landscapes of these regions, along with her extensive experience in the multinational pharmaceutical industry.

8th Health Technology Assessment

Η Μάγδα Χατζίκου, Partner PharmEcons Easy Access Ltd, ΣΕΠ Ελληνικό Ανοικτό Πανεπιστήμιο στο πλαίσιο της ομιλίας της στο 8ο Ετήσιο Συνέδριο ΗΤΑ με παράδειγμα την εφαρμογή HosmartAI (ένα επιδοτούμενο πρόγραμμα του Ορίζοντα 2020), αναφέρθηκε στην ανάγκη να τεθεί σύντομα το πλαίσιο αξιολόγησης των ιατροτεχνολογικών εφαρμογών και άλλων τεχνολογιών τεχνητής νοημοσύνης και στην Ελλάδα.

Proposal on the European Health Data Space

The European Health Data Space (‘EHDS’) is the first proposal of such domain-specific common European data spaces. It will address health-specific challenges to electronic health data access and sharing, is one of the priorities of the European Commission in the area of health 2 and will be an integral part of building a European Health Union.

Regulation on health technology assessment

The Regulation (EU) 2021/2282 on health technology assessment (HTAR) contributes to improving the availability for EU patients of innovative technologies in the area of health, such as medicines and certain medical devices. It ensures an efficient use of resources and strengthens the quality of HTA across the Union. It provides a transparent and inclusive framework by establishing a Coordination Group of HTA national or regional authorities, a stakeholder network and by laying down rules on the involvement in joint clinical assessments and joint scientific con-sultations of patients, clinical experts and other relevant experts. The HTAR will also reduce duplication of efforts for national HTA authorities and industry, facilitate business predictability and ensure the long-term sustainability of EU HTA cooperation.

HosmartAI

HosmartAI EU Project, an amazing and ambitious journey for Pharmecons Easy Access who will perform the economic evaluation of the AI technologies has just started!

On the last 9-10 February, took place the kick-off meeting of the new project HosmartAI – “Hospital Smart development based on AI”. The project is funded by €10 million under European Union’s Horizon 2020 research and innovation programme (Grant Agreement No 101016834).